Biogen News and Research

RSS
Elan second quarter total revenue increases 6% to $288.0 million

Elan second quarter total revenue increases 6% to $288.0 million

Premier research institutions, Biogen Idec partner to sequence genomes of patients with ALS

Premier research institutions, Biogen Idec partner to sequence genomes of patients with ALS

EvaluatePharma releases World Preview 2018 report

EvaluatePharma releases World Preview 2018 report

Biogen Idec, MS community partner to celebrate Fourth Annual World MS Day

Biogen Idec, MS community partner to celebrate Fourth Annual World MS Day

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

EU and U.S. regulatory authorities accept Biogen Idec’s BG-12 NDA for review

PDL first quarter total revenues decrease to $77.3 million

PDL first quarter total revenues decrease to $77.3 million

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Elan first quarter total revenue increases 17% to $288.4 million

Elan first quarter total revenue increases 17% to $288.4 million

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Biogen Idec launches FAMPYRA in Canada

Biogen Idec launches FAMPYRA in Canada

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Alzheimer's Association awards $4.2M grant to DIAN-Therapeutic Trials Unit

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec announces new easier to use injection for multiple sclerosis

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Biogen Idec, Samsung Biologics establish joint venture to develop and market biosimilars

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda's fourth quarter GAAP net income increases to $12.7 million

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan fourth quarter total revenue increases 18% to $271.0 million

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

Multiple sclerosis drug Gilenya under investigation by FDA and EMA